Potential utility of precision medicine for older adults with polypharmacy: a case series study
暂无分享,去创建一个
Joseph Finkelstein | George Hripcsak | Carol Friedman | G. Hripcsak | C. Friedman | J. Finkelstein | Manuel Cabrera | M. Cabrera
[1] J. Goldstein,et al. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. , 2005, Pharmacogenomics.
[2] Warfarin Dosing in a Patient with CYP2C9∗3∗3 and VKORC1-1639 AA Genotypes , 2014, Case reports in genetics.
[3] J. Saldivar,et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility , 2016, Pharmacogenomics and personalized medicine.
[4] Y. Kang,et al. Pharmacogenomics and Personalized Medicine , 2008, Methods in Pharmacology and Toxicology.
[5] M. Schwab,et al. META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS , 2013, Clinical pharmacology and therapeutics.
[6] Karen A. Hartman,et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. , 2010, The American journal of cardiology.
[7] Gregory M. Garrison,et al. Epidemiology of Polypharmacy Among Family Medicine Patients at Hospital Discharge , 2013, Journal of primary care & community health.
[8] B. Tarini,et al. Primary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literature , 2014, Genetics in Medicine.
[9] Joseph Hanlon,et al. Clinical consequences of polypharmacy in elderly , 2014, Expert opinion on drug safety.
[10] K. Ashcraft,et al. Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] R. Porcher,et al. Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs , 2014, Genetics in Medicine.
[12] K. J. Johansen Taber,et al. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties , 2014, Pharmacogenomics and personalized medicine.
[13] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[14] R. Altman,et al. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. , 2015, Mayo Clinic proceedings.
[15] M. Isidoro-García,et al. Primun non nocere, polypharmacy and pharmacogenetics. , 2015, Pharmacogenomics.
[16] Soma Das,et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.
[17] W Burke,et al. Primary care physicians' knowledge of and experience with pharmacogenetic testing , 2012, Clinical genetics.
[18] S. Bates,et al. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.
[19] D. Brixner,et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy , 2016, Journal of medical economics.
[20] Sukhminder Jit Singh Bajwa,et al. Polypharmacy and Potentially Inappropriate Medication Use as the Precipitating Factor in Readmissions to the Hospital , 2013, Journal of family medicine and primary care.
[21] Phil Schumm,et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. , 2008, JAMA.
[22] S. Goland,et al. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure , 2014, Journal of clinical pharmacy and therapeutics.
[23] T. Mamiya,et al. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. , 2014, Pharmacogenomics.
[24] Emily R. Hajjar,et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Carey,et al. A Critical Guide to Case Series Reports , 2003, Spine.
[26] Shufeng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.
[27] C. Jang,et al. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of carvediolol , 2007 .
[28] Masahiro Hiratsuka,et al. Genetic testing for pharmacogenetics and its clinical application in drug therapy. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[29] Christopher G Chute,et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.
[30] T. Obara,et al. Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists , 2015, Pharmacogenomics and personalized medicine.
[31] J. Stingl,et al. CYP450 genotype and pharmacogenetic association studies: a critical appraisal. , 2016, Pharmacogenomics.
[32] Jarrod W Heck,et al. CYP450 genotyping and cumulative drug-gene interactions: an update for precision medicine. , 2016, Personalized medicine.
[33] S. Greenberg. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012, Journal of the American Geriatrics Society.
[34] P. Gallagher,et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. , 2008, International journal of clinical pharmacology and therapeutics.
[35] M. Rieder,et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.
[36] O. Gottesman,et al. Implementation and utilization of genetic testing in personalized medicine , 2014, Pharmacogenomics and personalized medicine.
[37] L. Cavallari,et al. Role of cytochrome P450 genotype in the steps toward personalized drug therapy , 2011, Pharmacogenomics and personalized medicine.
[38] Joseph Finkelstein,et al. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity , 2009, International journal of chronic obstructive pulmonary disease.
[39] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[40] A. Lymperopoulos,et al. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol. , 2015, Current drug metabolism.
[41] Jing Li,et al. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy , 2011, Pharmacogenomics and personalized medicine.
[42] C. Campanelli. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012 .
[43] Harlan M Krumholz,et al. Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. , 2013, Journal of the American College of Cardiology.
[44] Geoffrey S Ginsburg,et al. Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable , 2015, The Annals of Family Medicine.
[45] A. Bast,et al. Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms , 2007, Alimentary pharmacology & therapeutics.
[46] D. Voora,et al. Delivering pharmacogenetic testing in a primary care setting , 2013, Pharmacogenomics and personalized medicine.
[47] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[48] Russ B Altman,et al. PharmGKB: the Pharmacogenomics Knowledge Base. , 2013, Methods in molecular biology.
[49] Magnus Ingelman-Sundberg,et al. Pharmacogenomic biomarkers: new tools in current and future drug therapy. , 2011, Trends in pharmacological sciences.
[50] Marc S. Williams,et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin , 2008, Genetics in Medicine.
[51] B. Carlson. Vanderbilt pioneers bedside genetics. , 2012, Biotechnology healthcare.
[52] H. Shin,et al. Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes , 2013, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[53] Joseph L. Kannry,et al. Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support , 2014, Journal of personalized medicine.
[54] Nicole A. Restrepo,et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. , 2013, Pharmacogenomics.